Cell & Gene Therapy World 2017

Cell & Gene Therapy World 2017 Agenda

Loading
  1. Registration & breakfast in the exhibition area
  1. How 2016/17’s big commercialization stories will shape cell & gene therapy marketplaces for years to come

  2. How 2016/17’s big commercialization stories will shape cell & gene therapy marketplaces for years to come

  3. How 2016/17’s big commercialization stories will shape cell & gene therapy marketplaces for years to come

  4. How 2016/17’s big commercialization stories will shape cell & gene therapy marketplaces for years to come

  5. How 2016/17’s big commercialization stories will shape cell & gene therapy marketplaces for years to come

  6. How 2016/17’s big commercialization stories will shape cell & gene therapy marketplaces for years to come

  1. Highlighting and addressing ‘critical path’ issues in bringing manufacturing processes from Phase I/II to commercial scale

  2. Highlighting and addressing ‘critical path’ issues in bringing manufacturing processes from Phase I/II to commercial scale

  3. Highlighting and addressing ‘critical path’ issues in bringing manufacturing processes from Phase I/II to commercial scale

  4. Highlighting and addressing ‘critical path’ issues in bringing manufacturing processes from Phase I/II to commercial scale

  5. Highlighting and addressing ‘critical path’ issues in bringing manufacturing processes from Phase I/II to commercial scale

  6. Highlighting and addressing ‘critical path’ issues in bringing manufacturing processes from Phase I/II to commercial scale

  1. Optimizing preclinical data packages for efficient cell & gene therapy clinical translation

  2. Optimizing preclinical data packages for efficient cell & gene therapy clinical translation

  3. Optimizing preclinical data packages for efficient cell & gene therapy clinical translation

  4. Optimizing preclinical data packages for efficient cell & gene therapy clinical translation

  1. Adoptive T cell immunotherapy business models: Who has the lead in removing barriers to commercial success?

  2. Adoptive T cell immunotherapy business models: Who has the lead in removing barriers to commercial success?

  3. Adoptive T cell immunotherapy business models: Who has the lead in removing barriers to commercial success?

  4. Adoptive T cell immunotherapy business models: Who has the lead in removing barriers to commercial success?

  1. Therapeutic area clinical update: Monogenic blood disorders

  2. Therapeutic area clinical update: Monogenic blood disorders

  3. Therapeutic area clinical update: Monogenic blood disorders

  4. Therapeutic area clinical update: Monogenic blood disorders

  5. Therapeutic area clinical update: Monogenic blood disorders

  1. How to win the collaboration game in global cell & gene therapy’s brave new world?

  2. How to win the collaboration game in global cell & gene therapy’s brave new world?

  3. How to win the collaboration game in global cell & gene therapy’s brave new world?

  4. How to win the collaboration game in global cell & gene therapy’s brave new world?

  1. Which combination therapy strategies will help realize the full potential of CAR T cell and TCR-based immunotherapies?

  2. Which combination therapy strategies will help realize the full potential of CAR T cell and TCR-based immunotherapies?

  3. Which combination therapy strategies will help realize the full potential of CAR T cell and TCR-based immunotherapies?

  4. Which combination therapy strategies will help realize the full potential of CAR T cell and TCR-based immunotherapies?

  1. Buffet lunch in the exhibition area
  1. Immuno-oncology combinations to unleash the full power of cancer vaccines and oncolytic virus therapies?

  2. Immuno-oncology combinations to unleash the full power of cancer vaccines and oncolytic virus therapies?

  3. Immuno-oncology combinations to unleash the full power of cancer vaccines and oncolytic virus therapies?

  4. Immuno-oncology combinations to unleash the full power of cancer vaccines and oncolytic virus therapies?

  1. Logistics Hub & Roundtable Discussions

  1. Investor insights to prepare your company for tomorrow’s cell & gene therapy funding environment

  2. Investor insights to prepare your company for tomorrow’s cell & gene therapy funding environment

  3. Investor insights to prepare your company for tomorrow’s cell & gene therapy funding environment

  1. Will a ‘perfect storm’ of scientific and technological breakthroughs herald a bright future for the global cord blood and tissue sector?

  2. Will a perfect storm of scientific and technological breakthroughs herald a bright future for the global cord blood and tissue sector?

  3. Public and private cord blood and tissue bank business models

  4. Public and private cord blood and tissue bank business models

  1. Technology updates: Cord blood cell expansion

  2. Technology updates: Cord blood cell expansion

  3. Technology updates: Cord blood cell expansion

  4. Technology updates: Cord blood cell expansion

  5. Technology updates: Cord blood cell expansion

  6. Technology updates: Cord blood cell expansion

  1. Buffet lunch in the exhibition area
  1. Product characterization & bioanalytics: Identifying and harnessing genuinely disruptive tools at the cutting edge

  2. Product characterization & bioanalytics: Identifying and harnessing genuinely disruptive tools at the cutting edge

  3. Product characterization & bioanalytics: Identifying and harnessing genuinely disruptive tools at the cutting edge

  4. Product characterization & bioanalytics: Identifying and harnessing genuinely disruptive tools at the cutting edge

  5. Product characterization & bioanalytics: Identifying and harnessing genuinely disruptive tools at the cutting edge

  1. Therapeutic area clinical update: Ophthalmology

  2. Therapeutic area clinical update: Ophthalmology

  3. Therapeutic area clinical update: Ophthalmology

  4. Therapeutic area clinical update: Ophthalmology